Advanced Compounding Solutions (New England Life Care, Inc.), Woburn, MA

Is Advanced Compounding Solutions (New England Life Care, Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “De-registered as an Outsourcing Facility”.

Does Advanced Compounding Solutions (New England Life Care, Inc.) hold a Massachusetts pharmacy license?

State board of pharmacy records for Massachusetts are not checked: the board’s website refused automated requests, and this index does not work around blocks. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002131 for NEW ENGLAND LIFE CARE INC (dba HOME INFUSION), WOBURN, MA, status ACTIVE (CURRENT) and license PCN.0000900 for NEW ENGLAND LIFE CARE, WOBURN, MA, status INACTIVE, as of Nov 15, 2026.

Has Advanced Compounding Solutions (New England Life Care, Inc.) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (May 16, 2023), 1 untitled letter (Aug 21, 2019), 1 state referral letter (Jul 31, 2019) and 1 FMD-145 letter (Jul 31, 2019) for Advanced Compounding Solutions (New England Life Care, Inc.). State board of pharmacy records for Massachusetts are not checked: the board’s website refused automated requests, and this index does not work around blocks. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
New England Life Care, Inc.; Advanced Compounding Solutions
Location
Woburn, MA
Type as FDA labels it
503A
FDA’s note
De-registered as an Outsourcing Facility
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
1
Latest action on that page
May 16, 2023
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 VAI; 1 published Form 483
Form 483 text on this page
2 Form 483s, 12 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy under 2 entries in the same city (New England Life Care, Inc., (dba Advanced Compounding Solutions), 503A; New England Life Care, Inc., 503A), with 5 distinct dated actions between them.

Document
May 16, 2023Warning letterWarning Letter Issued 05/16/2023FDA copy (archived)
Apr 28, 2022Form 483483 Issued 04/28/2022FDA copy (archived)
Aug 21, 2019Untitled letterUntitled Letter Issued 8/21/2019FDA copy (archived)
Jul 31, 2019State referral letterState Referral Letter Issued 07/31/2019Not linked by FDA
Jul 31, 2019FMD-145 letterFMD-145 Letter Issued 07/31/2019Not linked by FDA

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists New England Life Care, Inc., Woburn, MA (FEI number 3014174643), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Apr 28, 2022Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30141746431168143
Feb 8, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30141746431040234

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 12 numbered observations in all, across 2 inspections ending Feb 8, 2018 to Apr 28, 2022. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Mar 21, 2022 to Apr 28, 2022: 7 observations

Firm on the cover
New England Life Care, Inc. dba Advanced Compounding Solutions, 4 Constitution Way St e L, Woburn, MA 01801 -1042
FEI number
3010371376
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
One Montvale Avenue Stoneham, MA 02180
Matched to this page by
firm name, city and state on the cover; linked from actions page
FDA document
Read the full 483 (Internet Archive copy FDA links)

Observation 1

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been aheady distributed.

Specifically,

A. Your firm failed to thoroughly investigate environmental monitoring excursions and has continued to produce product while investigations into environmental excursions exceeding your action limits in ISO-5 hoods are open and incomplete:

• The firm was unable to provide documentation of investigations for 21 out of 24 excursions recorded so far in 2022, five of which were logged in March 2022 prior to the on-site inspection. Open excursions include:

o On 1/13/2022, your firm recorded two viable air excursions in ISO-5 hoods 32LFH-05 and 03LFH-03 involving the gram-positive, spore-forming organism Bacillus lichenifermis. On that day, your firm produced Ephedrine 5 mg/mL;5mL lot <Redacted B4>, which your quality unit released into distribution on 2/1/2022.

o On 1/14/2022, your firm recorded a personnel monitoring excursion involving the gram-­positive, spore-forminng organism Brevibacillus brevis. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.

Specifically,

A. On 03/21/2022, pharmacy technicians were observed conducting manufacturing operations for Media Fill Lot# <Redacted B4> During the operation, multiple manufacturing operators were observed with <Redacted B4>. The <Redacted B4> created a <Redacted B4> forehead exposing the operators' skin which could allow particulates to enter the ISO 5 Aseptic and ISO 7 areas of the facility.

B. On 03/24/2022, we observed the production of Phenylephrine 80mcg/mL; 10mL Lot # <Redacted B4> in LFH 2LFH-02, and Rocuronium l0mg/mL; 5mL Lot # <Redacted B4> in LFH 34LFH-07. During manufacturing operations, the following was observed:

1. During the production of Phenylephrine 80mcg/mL; l0mL in LFH 2LFH-02:

f6)l6)1 • Operator laced a hand-held particle counter meter directly against the face of the ISO 5 filter, blocking first pass air over syringe caps during manufacturing.

• Operator <Redacted B4> placed an air sampler directly against the face of the ISO 5 LFH filter, which was blocking first pass air over the ISO 5 work zone. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 3

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A. Your firm failed to validate the cleaning process used to perform cleaning operations in your facility. Your firm uses sterile <Redacted B4>,<Redacted B4> sterile, sterile <Redacted B4> and sterile <Redacted B4> to clean and disinfect the ISO 5, ISO 7, and ISO 8 areas of your facility, and to clean and disinfect the equipment, components and materials entering into each area of the facility. Your firm failed to demonstrate that the cleaning processes and cleaning agents used are sufficient to maintain aseptic conditions in your facility during the production of sterile drug products.

B. Your aseptic processing areas were insanitary or difficult to clean:

AM ENDMENT 1

• Surfaces are difficult to clean due to damage and deterioration. On 3/24/2022, rust and paint chipping were observed on the exterior of ISO-5 hoods 02LFH-02, 04LFH-04, 33LFH-06, and 34LFH-07 in the ISO-7 environment, located within inches of the ISO-5 work surface. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 4

Buildings used in the manufacturing, processing, packing and holding of a drug product are not maintained in a good state of repair.

Specifically, structures intended to maintain control of the ISO-7 environment in the compounding room (Rm 5-109) exhibit damage or deterioration:

• Automatic drop bottoms for maintaining classified environments in the cleanroom suite are missing or damaged. Examples include doors between the unclassified warehouse and the ISO-8 gowning room (Rm 5-102), the ISO-8 gowning room (Rm 5-102) and the ISO-7 ante room (Rm 5-107), the ISO-7 ante room (Rm 5-107) and the ISO-7 compounding room (Rm 5-109), and the unclassified warehouse and the ISO-8 material wipe down room (Rm 5-104).

• The rubber gasket on the door between the ISO-8 gowning room (Rm 5-102) and ISO-7 ante room (Rm 5-107) was damaged and loose.

• The design of the sliding door between the unclassified warehouse and the ISO-8 finished product room (Rm 5-112) leaves an unsealed gap between the door and the frame when the door is in the closed position. Additional gaps were observed due to the door not being flush with the frame and floor.

AM ENDMENT 1

frame and floor. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 5

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

AME NDMENT 1

Specifically,

A. You conducted dynamic Air Flow Pattern Visualization testing (smoke studies) for ISO 5 Laminar Flow Hoods (LFHs) lLFH-01, 2LFH-02 and 34LFH-07 on 10/20/2021 and for 33LFH-06 on 10/21/2021, which are used to produce sterile diug products. The smoke studies performed were deficient:

• The 10/20/2021 and 10/21/2021 studies for the LFHs do not include the transfer of all startig components and materials into the ISO 5 classified areas.

• The 10/20/2021 and 10/21/2021 studies for the LFHs failed to include all manipulations and transfers performed by the operator during production.

B. On 03/24/2022, the air returns inside the ISO-7 compounding room were observed to be blocked by large pieces of equipment.

• The air return in the southwest comer of the ISO-7 compounding room (Rm 5-109) is entirely occluded by Hood 34LFH-07.

• The air return in the northwest comer of the ISO-7 compounding room is mostly blocked by Hood 02LFH-02.

Observation 6

Samples of representative units were not collected and visually examined for correct labeling at the completion of finishing operations.

Specifically, your firm failed to visually examine finished sterile drug products at the end of finishing operations to ensure each lot of drug product was correctly labeled. Your procedures do not require a representative number of finished drug products be sampled and then visually examined for correct labeling prior to release. In addition, product batch records do not indicate if sterile finished drug product's labeling has been examined at the end of finishing operations to confnm each lot contains the appropriate label for the manufactured sterile drug product.

AM ENDMENT 1

representative number of finished drng products be sampled and then visually examined for coITect labeling prior to release. In addition, product batch records do not indicate if sterile finished drng product's labeling has been examined at the end of finishing operations to confnm each lot contains the appropriate label for the manufactured sterile diu g product.

Observation 7

The labels of your outsourcing facility's drug products are deficient.

Specifically, the labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A). Specifically, the dosage form is not found on your drug product labels.

Examples of your drug product labels that do not contain this information:

• Diltiazem 125mg in l00mL bag

• Norepinephrine Bitartrate 8 mg Dextrose 5% 250 mL bag

• Vancomycin HCL 750 mg in 0.9% Sodium Chloride 250 mL bag

• Phenylephrine 20mg in 250mL bag

Inspection Feb 8, 2018: 5 observations

Firm on the cover
New England Life Care, Inc., 4 Constitution Way Suite J, Woburn, MA 01 801 -1 042
FEI number
3014174643
Establishment type on the cover
Producer of Sterile Drug Products
FDA district office on the cover
One Montvale Avenue Stoneham, MA 02180
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Personnel moved rapidly in the vicinity of open sterile units and instruments, which disrupted the airflow and increased the risk of bringing lesser quality air into the ISO 5 classified aseptic processing area.

Specifically,

I observed the following:

On January 31, 2018, Pharmacy Technician <Redacted B6> had prepared materials and suppl ies for aseptic processing and filing activities in the unclassified Pharmacy area with her bare hands after sanitizing the materials and supplies with <Redacted B4>

On January 31, 2018, Pharmacy Technician <Redacted B6> was sterile processing TPN prod uc ts in Ho od <Redacted B4> RX# <Redacted B6> I observed that <Redacted B6> consistently put the top of her head (exposing the skin from her neck and face) into the hood along with p arts of her shoulder. I also noted on Febr uary 1, 2018 , an instance in which <Redacted B6> le ft the ISO 5 hood for supplies in the ISO 8 area and upon her return to the ISO 5 <Redact ed B6> neglected to change and/or sanitize her gloves prior to entry into the I SO 5 Hood. <Redacted B6> had processed RX#'s <Redacted B6> that day. ...

Read the full 483 (PDF on fda.gov)

Observation 2

You had inadequate HEPA filter coverage and airflow over the area to which sterile product was exposed.

Specifically,

The requalifications of the <Redacted B4> ISO 5 Laminar Flow Hoods Models <Redacted B4> were inadequate in that the static and dynamic smokes studies conducted did not demonstrate the actual setup and aseptic operations within the Laminar Flow Hoods as used by the fom during routine processing operations. For example, the August 2017 requalification of these hoods indicates that static and dynamic smoke studies were conducted; however, there was inadequate documentation of said activities within the report. Furthermore, Hood <Redacted B4> is routinely used for TPN processing operations which contains a <Redacted B4> unit with numerous accessories which comprise. approximately <Redacted B4> of the hood's capacity and without adequately documenting the airflow smoke pattern it cannot be determined that this setup would have an effect on the unidirectional airflow within the hood to ensure that the sterility of the product is maintained. ...

Read the full 483 (PDF on fda.gov)

Observation 3

You produced beta-lactam drugs without providing adequate cleaning of utensils to prevent cross-contamination.

Specifically,

The film's cleanroom design and operational procedures do not provide adequate segregation of Beta-Lactam antibiotic products from general drugs produced. Beta-Lactam antibiotics are processed in the same laminar flow hoods (Hoods<Redacted B4> as other general diug products separated only by a wipe down with <Redacted B4> For example:

On January 31, 2018, Pharmacy Technician <Redacted B6> processed the following products in Hood <Redacted B4> lO:OOam -Imipenem-Cilastatin 500mg in 100mL NS (RX# <Redacted B6>, 12:00pm - Cefepime 2000mg in 20mL SWFI (RX#<Redacted B6> 12:30pm -fron Sucrose 20mg in lOmL NS (RX#<Redacted B6> and 1:30pm-Ampicillin 12g in 620mL NS (RX# <Redacted B6>

On February 1, 2018, Pharmacy Technician <Redacted B6> processed the following products in Hood <Redacted B4> 10:30am Ceftriaxone 2000mg in 20mL SWFI (RX# <Redacted B6>, 11:OOam -Ceftriaxone 2g in 20mL SWFI (RX# <Redacted B6> and 3:00pm-Methadone 50mmg in lOOmL NS (RX# <Redacted B6> ...

Read the full 483 (PDF on fda.gov)

Observation 4

Non-microbial contamination was observed in your production area.

Specifically,

On January 31, 2018, I observed several ceiling tiles within the Pharmacy that had what appeared to be water stains and/or had stains that had been painted over. Also noted was an unknown material splashed on the exterior side to the door leading into the ISO 8 Gowning Room.

Observation 5

Disinfecting agents and cleaning pads and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.

Specifically,

The firm uses non-sterile disinfectants for <Redacted B4> sanitization of the interior surfaces of the ISO 5 Hoods <Redacted B4>. For example, technicians will sanitize and disinfect the ISO 5 Hoods on <Redacted B4> basis using <Redacted B4> Brand <Redacted B4> Disinfectant Cleaner which is non-sterile. These ISO 5 Hoods are used for sterile compounding and filling operations.

State board of pharmacy records

State board of pharmacy records for Massachusetts are not checked: the board’s website refused automated requests, and this index does not work around blocks.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002131NONRESIDENT PHARMACYNEW ENGLAND LIFE CARE INC (dba HOME INFUSION)WOBURN, MAACTIVE (CURRENT)
PCN.0000900NONRESIDENT PHARMACYNEW ENGLAND LIFE CAREWOBURN, MAINACTIVE

Same name at other locations

FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.